Published in Neth J Med on November 01, 2002
Tunnelled central venous catheter-related problems in the early phase of haematopoietic stem cell transplantation and effects on transplant outcome. Turk J Haematol (2015) 1.08
18F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation. Eur J Nucl Med Mol Imaging (2011) 0.92
Incidents and complications of totally implanted vascular access devices in children: a prospective study. Patient Saf Surg (2008) 0.79
Endovascular stenting for the management of port-a-cath associated superior vena cava syndrome. Emerg Radiol (2008) 0.75
Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med (2012) 15.43
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol (2009) 2.74
KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer (2011) 2.16
Breast cancer size estimation with MRI in BRCA mutation carriers and other high risk patients. Eur J Radiol (2013) 2.06
Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg (2013) 1.98
Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol (2009) 1.87
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer (2009) 1.75
Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol (2002) 1.52
Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol (2007) 1.42
Blistering of the hand in a breast cancer patient. Extravasation. Neth J Med (2011) 1.41
Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol (2008) 1.31
Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol (2012) 1.31
The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer (2010) 1.26
Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs (2008) 1.21
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer (2003) 1.21
Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer (2010) 1.21
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol (2005) 1.17
Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev (2009) 1.14
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer (2008) 1.07
DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer. Ann Oncol (2009) 1.07
Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Ann Oncol (2006) 1.06
Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother (2008) 1.06
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer (2009) 1.03
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol (2014) 1.03
FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma. Ann Oncol (2006) 1.01
Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas. Invest New Drugs (2006) 1.00
Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer (2002) 1.00
Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol (2002) 0.99
Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol (2003) 0.98
Analysis of dendritic cell trafficking using EGFP-transgenic mice. Immunol Lett (2003) 0.98
A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. Br J Cancer (2010) 0.96
Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. Ann Oncol (2004) 0.96
Limitations of cytokeratin 20 RT-PCR to detect disseminated tumour cells in blood and bone marrow of patients with colorectal cancer: expression in controls and downregulation in tumour tissue. Mol Pathol (2002) 0.95
Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). Ann Oncol (2014) 0.93
Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil. NMR Biomed (2007) 0.93
Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. Ann Oncol (2010) 0.93
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours. Eur J Cancer (2006) 0.93
Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array. Br J Cancer (2009) 0.92
Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. Cancer Imaging (2012) 0.92
Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases. Eur J Surg Oncol (2005) 0.92
In vivo magnetic resonance spectroscopy of liver tumors and metastases. World J Gastroenterol (2011) 0.90
Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. Contrast Media Mol Imaging (2014) 0.90
Phase II study of E7070 in patients with metastatic melanoma. Ann Oncol (2005) 0.90
Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). Br J Surg (2015) 0.89
The management of clear cell sarcoma. Eur J Surg Oncol (2003) 0.87
Detection of disseminated tumour cells in blood and bone marrow samples of patients undergoing hepatic resection for metastasis of colorectal cancer. Br J Surg (2003) 0.86
Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease. Eur J Surg Oncol (2006) 0.86
Arm morbidity after complete axillary lymph node dissection for breast cancer. Acta Chir Belg (2003) 0.85
In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients. Cancer Immunol Immunother (2007) 0.85
Relevance of disseminated tumour cells in blood and bone marrow of patients with solid epithelial tumours in perspective. Eur J Surg Oncol (2003) 0.84
The oncological implications of immediate breast reconstruction. Eur J Surg Oncol (2004) 0.84
Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma. Br J Cancer (2003) 0.83
GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br J Cancer (2008) 0.83
The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab. Ann Oncol (2010) 0.82
Menopausal status and adjuvant hormonal therapy for breast cancer patients: a practical guideline. Crit Rev Oncol Hematol (2012) 0.82
New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide. Biomarkers (2015) 0.80
Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer. Lung Cancer (2007) 0.80
Residual disease after excision of non-palpable breast tumours: analysis of tumour characteristics. Eur J Surg Oncol (2004) 0.79
How can communication by oncologists enhance patients' trust? An experimental study. Ann Oncol (2014) 0.79
Biological therapy of colorectal cancer. Eur J Cancer (2002) 0.79
The role of physical activity and physical fitness in postcancer fatigue: a randomized controlled trial. Support Care Cancer (2013) 0.79
Real-world resource use and costs of adjuvant treatment for stage III colon cancer. Eur J Cancer Care (Engl) (2013) 0.79
Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer? Ann Oncol (2005) 0.79
Assessment of Blood Hemodynamics by USPIO-Induced R(1) Changes in MRI of Murine Colon Carcinoma. Appl Magn Reson (2010) 0.79
Small but significant survival benefit in patients who undergo routine follow-up after colorectal cancer surgery. Eur J Surg Oncol (2004) 0.79
Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach. Invest New Drugs (2013) 0.78
A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer. Ann Oncol (2009) 0.78
Detection and clinical relevance of tumor cells in blood and bone marrow of patients with colorectal cancer. Anticancer Res (2003) 0.78
Improved metastasis-free survival in nonadjuvantly treated postmenopausal breast cancer patients with chemokine receptor 5 del32 frameshift mutations. Int J Cancer (2014) 0.78
Cryosurgery of tumor tissue causes endotoxin tolerance through an inflammatory response. Anticancer Res (2003) 0.77
A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion. Target Oncol (2014) 0.77
Variations in treatment of ductal carcinoma in situ of the breast: a population-based study in the East Netherlands. Eur J Surg Oncol (2006) 0.77
Plasma gelatinase activity does not reflect disease activity after operation for colorectal cancer. Oncology (2005) 0.77
Modulation of hypoxia in murine liver metastases of colon carcinoma by nicotinamide and carbogen. Radiat Res (2005) 0.77
Tumor-receptor imaging in breast cancer: a tool for patient selection and response monitoring. Curr Mol Med (2013) 0.77
Breast cancer screening: using familiality for earlier detection. Breast (2002) 0.76
Mitochondrial microsatellite instability in patients with metastatic colorectal cancer. Virchows Arch (2015) 0.76
Hepatic veno-occlusive disease after neoadjuvant treatment of colorectal liver metastases with oxaliplatin: a lesson of the month. Eur J Surg Oncol (2007) 0.75
Investigations for a multi-marker RT-PCR to improve sensitivity of disseminated tumor cell detection. Anticancer Res (2003) 0.75
Regarding: 'Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array'. Br J Cancer (2010) 0.75
Statistical trial designs and clinical practice: are they compatible? Onkologie (2003) 0.75
[Medical perception of the hereditary aspects of cancer in The Netherlands, 1900-1980]. Ned Tijdschr Geneeskd (2007) 0.75
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. Br J Cancer (2015) 0.75
Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01). Breast Cancer Res Treat (2015) 0.75
[The mammary duct fistula: a persistent problem that can be treated adequately]. Ned Tijdschr Geneeskd (2004) 0.75
[Detailed pathological examination of the sentinel lymph nodes in order to detect micrometastases: no clinical relevance in patients with breast cancer]. Ned Tijdschr Geneeskd (2005) 0.75
Performing phase III clinical trials: never an easy task. Onkologie (2002) 0.75
Treatment of liver metastases from colorectal cancer. Neth J Med (2006) 0.75
New diagnostic techniques in staging in the surgical treatment of cutaneous malignant melanoma. Eur J Surg Oncol (2002) 0.75